Salix Pharmaceuticals (SLXP) 105.88 $SLXP
Salix Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.65%
Comtex SmarTrend(R) - Tue Dec 02, 4:15PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $101.75 to a high of $104.97. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $104.21 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 105.88 (+1.83)
SLXP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
PR Newswire - Tue Dec 02, 11:35AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(NasdaqGS: SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 105.88 (+1.83)
Hagens Berman Reminds Investors of January 6th Lead Plaintiff Deadline in Suit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Mon Dec 01, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors of the upcoming Lead Plaintiff deadline in the lawsuit filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company" . The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff.
SLXP: 105.88 (+1.83)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Salix Pharmaceuticals of Class Action Lawsuit and Upcoming Deadline -- SLXP
GlobeNewswire - Fri Nov 28, 2:00AM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company" (Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
SLXP: 105.88 (+1.83)
Pharming Reports on Financial Results for the First Nine Months of 2014
PR Newswire Europe - Wed Nov 26, 8:17PM CST
LEIDEN, The Netherlands, October 30, 2014 /PRNewswire/ --
SLXP: 105.88 (+1.83)
Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
PR Newswire Europe - Wed Nov 26, 12:16PM CST
LEIDEN, The Netherlands, October 13, 2014 /PRNewswire/ --
SLXP: 105.88 (+1.83)
INVESTOR ALERT: Class Action Lawsuit Against Salix Pharmaceuticals, Ltd. Announced by Law Offices of Howard G. Smith
Business Wire - Wed Nov 26, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who have losses of $250,000 or more are encouraged to contact the firm for more information.
SLXP: 105.88 (+1.83)
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Salix Pharmaceuticals, Ltd. - SLXP
GlobeNewswire - Tue Nov 25, 4:00PM CST
The Rosen Law Firm announces a class action lawsuit was filed on behalf of purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014. The lawsuit seeks to recover damages for Salix investors under the federal securities laws.
SLXP: 105.88 (+1.83)
Salix Pharmaceuticals Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Tue Nov 25, 9:57AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. ("Salix" or "Company" (NasdaqGS: SLXP) and several officers and directors for acts taken during the period of November 8, 2013 to November 6, 2014 (the "Class Period" .
SLXP: 105.88 (+1.83)
Salix Pharmaceuticals Announces Plan to Augment Board of Directors
Business Wire - Mon Nov 24, 3:01PM CST
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company" today announced that it has engaged Russell Reynolds Associates, a nationally recognized search firm, to conduct a comprehensive search to assist the Company in identifying experienced, highly qualified individuals to serve as independent members of the Company's Board of Directors. The search process will seek to identify proven business leaders with complementary and relevant expertise to increase the depth, skillset and perspective of the Salix Board.
SLXP: 105.88 (+1.83)
SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Mon Nov 24, 2:19PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 105.88 (+1.83)
Post Earnings Update: Salix Pharmaceuticals Has Sunk 25.7% Lower in Past 2 Weeks (SLXP)
Comtex SmarTrend(R) - Mon Nov 24, 9:24AM CST
When Salix Pharmaceuticals (NASDAQ:SLXP) reported earnings two weeks ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.54 on sales of $392.3 million. The company actually reported EPS of $1.53 on sales of $354.7 million, missing EPS estimates by $0.01 and missing revenue estimates by $37.6 million. Since the company's report, shares of Salix Pharmaceuticals have fallen from $138.55 to $102.90, representing a loss of 25.7% in the past 18 days.
SLXP: 105.88 (+1.83)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Salix Pharmaceuticals Inc. (SLXP) to Contact the Firm
GlobeNewswire - Fri Nov 21, 8:45PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Salix Pharmaceuticals Inc. ("Salix" or the "Company" (Nasdaq:SLXP) of the January 6, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Salix and certain executives.
SLXP: 105.88 (+1.83)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Salix Pharmaceuticals, Ltd. To Contact Brower Piven Before The January 6, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Nov 19, 8:34PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (Nasdaq: SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff.
SLXP: 105.88 (+1.83)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 267.50 (+1.66), QLTI: 3.91 (+0.02), VRX: 144.33 (-0.94), AGN: 213.71 (+1.74), SHPG: 216.01 (+1.26), AUXL: 33.77 (-0.11), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36), ABT: 45.49 (-0.19), ENDP: 70.69 (-0.53), AKRX: 39.28 (-0.90), PFE: 31.67 (-0.08), INCY: 74.12 (-0.54), SLXP: 105.88 (+1.83), MYL: 58.23 (unch), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14), ACHN: 13.80 (+0.03), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), ICPT: 138.02 (+1.02), TEVA: 57.50 (+0.22), NVS: 95.77 (+0.11)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 267.50 (+1.66), QLTI: 3.91 (+0.02), VRX: 144.33 (-0.94), AGN: 213.71 (+1.74), SHPG: 216.01 (+1.26), AUXL: 33.77 (-0.11), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36), ABT: 45.49 (-0.19), ENDP: 70.69 (-0.53), AKRX: 39.28 (-0.90), PFE: 31.67 (-0.08), INCY: 74.12 (-0.54), SLXP: 105.88 (+1.83), MYL: 58.23 (unch), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14), ACHN: 13.80 (+0.03), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), ICPT: 138.02 (+1.02), TEVA: 57.50 (+0.22), NVS: 95.77 (+0.11)
SmarTrend Watching for Potential Pullback in Shares of Salix Pharmaceuticals After 4.13% Gain
Comtex SmarTrend(R) - Tue Nov 18, 4:04PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $100.91 to a high of $106.10. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $103.46 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 105.88 (+1.83)
Post Earnings Update: Salix Pharmaceuticals Has Sunk 26.1% Lower in Past Week (SLXP)
Comtex SmarTrend(R) - Mon Nov 17, 3:22PM CST
When Salix Pharmaceuticals (NASDAQ:SLXP) reported earnings a week ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.54 on sales of $392.3 million. The company actually reported EPS of $1.53 on sales of $354.7 million, missing EPS estimates by $0.01 and missing revenue estimates by $37.6 million. Since the company's report, shares of Salix Pharmaceuticals have fallen from $138.55 to $102.32, representing a loss of 26.1% in the past 11 days.
SLXP: 105.88 (+1.83)
Watch for Salix Pharmaceuticals to Potentially Pullback After Gaining 5.50% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 3:51PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $97.98 to a high of $103.46. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $100.23 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 105.88 (+1.83)
Upgrade Alert for Salix Pharmaceuticals (SLXP)
Comtex SmarTrend(R) - Fri Nov 14, 7:05AM CST
Salix Pharmaceuticals (NASDAQ:SLXP) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $96.99 on volume of 3.9 million shares, above average daily volume of 2.9 million. There is potential upside of 73.8% for shares of Salix Pharmaceuticals based on a current price of $96.99 and an average consensus analyst price target of $168.59. Salix Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $124.39 and find additional resistance at the 50-day MA of $142.49.
SLXP: 105.88 (+1.83)
Salix Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 1.65%
Comtex SmarTrend(R) - Tue Dec 02, 4:15PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $101.75 to a high of $104.97. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $104.21 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 105.88 (+1.83)
SLXP SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
PR Newswire - Tue Dec 02, 11:35AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(NasdaqGS: SLXP) securities between November 8, 2013 and November 6, 2014. SLXP: 105.88 (+1.83)
Hagens Berman Reminds Investors of January 6th Lead Plaintiff Deadline in Suit Filed Against Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)
GlobeNewswire - Mon Dec 01, 7:30AM CST
Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors of the upcoming Lead Plaintiff deadline in the lawsuit filed against Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) ("Salix" or "the Company"
. The suit is pending in U.S. District Court for the Southern District of New York, and investors have until January 6, 2015 to move for lead plaintiff. SLXP: 105.88 (+1.83)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Salix Pharmaceuticals of Class Action Lawsuit and Upcoming Deadline -- SLXP
GlobeNewswire - Fri Nov 28, 2:00AM CST
Pomerantz LLP has filed a class action lawsuit against Salix Pharmaceuticals Ltd ("Salix" or the "Company"
(Nasdaq:SLXP) and certain of its officers. The class action, filed in United States District Court, Eastern District of North Carolina, Western Division, and docketed under 14-cv-00804, is on behalf of a class consisting of all persons or entities who purchased Salix securities between August 7, 2014 and November 6, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . SLXP: 105.88 (+1.83)
Pharming Reports on Financial Results for the First Nine Months of 2014
PR Newswire Europe - Wed Nov 26, 8:17PM CST
LEIDEN, The Netherlands, October 30, 2014 /PRNewswire/ --
SLXP: 105.88 (+1.83)
Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
PR Newswire Europe - Wed Nov 26, 12:16PM CST
LEIDEN, The Netherlands, October 13, 2014 /PRNewswire/ --
SLXP: 105.88 (+1.83)
INVESTOR ALERT: Class Action Lawsuit Against Salix Pharmaceuticals, Ltd. Announced by Law Offices of Howard G. Smith
Business Wire - Wed Nov 26, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of the securities of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(NASDAQ:SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who have losses of $250,000 or more are encouraged to contact the firm for more information. SLXP: 105.88 (+1.83)
EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Against Salix Pharmaceuticals, Ltd. - SLXP
GlobeNewswire - Tue Nov 25, 4:00PM CST
The Rosen Law Firm announces a class action lawsuit was filed on behalf of purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014. The lawsuit seeks to recover damages for Salix investors under the federal securities laws.
SLXP: 105.88 (+1.83)
Salix Pharmaceuticals Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Business Wire - Tue Nov 25, 9:57AM CST
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Salix Pharmaceuticals, Ltd. ("Salix" or "Company"
(NasdaqGS: SLXP) and several officers and directors for acts taken during the period of November 8, 2013 to November 6, 2014 (the "Class Period" . SLXP: 105.88 (+1.83)
Salix Pharmaceuticals Announces Plan to Augment Board of Directors
Business Wire - Mon Nov 24, 3:01PM CST
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company"
today announced that it has engaged Russell Reynolds Associates, a nationally recognized search firm, to conduct a comprehensive search to assist the Company in identifying experienced, highly qualified individuals to serve as independent members of the Company's Board of Directors. The search process will seek to identify proven business leaders with complementary and relevant expertise to increase the depth, skillset and perspective of the Salix Board. SLXP: 105.88 (+1.83)
SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Mon Nov 24, 2:19PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014. SLXP: 105.88 (+1.83)
Post Earnings Update: Salix Pharmaceuticals Has Sunk 25.7% Lower in Past 2 Weeks (SLXP)
Comtex SmarTrend(R) - Mon Nov 24, 9:24AM CST
When Salix Pharmaceuticals (NASDAQ:SLXP) reported earnings two weeks ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.54 on sales of $392.3 million. The company actually reported EPS of $1.53 on sales of $354.7 million, missing EPS estimates by $0.01 and missing revenue estimates by $37.6 million. Since the company's report, shares of Salix Pharmaceuticals have fallen from $138.55 to $102.90, representing a loss of 25.7% in the past 18 days.
SLXP: 105.88 (+1.83)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Salix Pharmaceuticals Inc. (SLXP) to Contact the Firm
GlobeNewswire - Fri Nov 21, 8:45PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Salix Pharmaceuticals Inc. ("Salix" or the "Company"
(Nasdaq:SLXP) of the January 6, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Salix and certain executives. SLXP: 105.88 (+1.83)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Salix Pharmaceuticals, Ltd. To Contact Brower Piven Before The January 6, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Nov 19, 8:34PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company"
(Nasdaq: SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff. SLXP: 105.88 (+1.83)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 267.50 (+1.66), QLTI: 3.91 (+0.02), VRX: 144.33 (-0.94), AGN: 213.71 (+1.74), SHPG: 216.01 (+1.26), AUXL: 33.77 (-0.11), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36), ABT: 45.49 (-0.19), ENDP: 70.69 (-0.53), AKRX: 39.28 (-0.90), PFE: 31.67 (-0.08), INCY: 74.12 (-0.54), SLXP: 105.88 (+1.83), MYL: 58.23 (unch), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14), ACHN: 13.80 (+0.03), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), ICPT: 138.02 (+1.02), TEVA: 57.50 (+0.22), NVS: 95.77 (+0.11)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 267.50 (+1.66), QLTI: 3.91 (+0.02), VRX: 144.33 (-0.94), AGN: 213.71 (+1.74), SHPG: 216.01 (+1.26), AUXL: 33.77 (-0.11), ABBV: 69.57 (+1.07), SNY: 46.75 (-1.36), ABT: 45.49 (-0.19), ENDP: 70.69 (-0.53), AKRX: 39.28 (-0.90), PFE: 31.67 (-0.08), INCY: 74.12 (-0.54), SLXP: 105.88 (+1.83), MYL: 58.23 (unch), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25), GSK: 45.89 (-0.82), BMY: 58.89 (-0.14), ACHN: 13.80 (+0.03), MRK: 60.92 (+0.34), AZN: 73.94 (+0.12), ICPT: 138.02 (+1.02), TEVA: 57.50 (+0.22), NVS: 95.77 (+0.11)
SmarTrend Watching for Potential Pullback in Shares of Salix Pharmaceuticals After 4.13% Gain
Comtex SmarTrend(R) - Tue Nov 18, 4:04PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $100.91 to a high of $106.10. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $103.46 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 105.88 (+1.83)
Post Earnings Update: Salix Pharmaceuticals Has Sunk 26.1% Lower in Past Week (SLXP)
Comtex SmarTrend(R) - Mon Nov 17, 3:22PM CST
When Salix Pharmaceuticals (NASDAQ:SLXP) reported earnings a week ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.54 on sales of $392.3 million. The company actually reported EPS of $1.53 on sales of $354.7 million, missing EPS estimates by $0.01 and missing revenue estimates by $37.6 million. Since the company's report, shares of Salix Pharmaceuticals have fallen from $138.55 to $102.32, representing a loss of 26.1% in the past 11 days.
SLXP: 105.88 (+1.83)
Watch for Salix Pharmaceuticals to Potentially Pullback After Gaining 5.50% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 3:51PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $97.98 to a high of $103.46. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $100.23 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 105.88 (+1.83)
Upgrade Alert for Salix Pharmaceuticals (SLXP)
Comtex SmarTrend(R) - Fri Nov 14, 7:05AM CST
Salix Pharmaceuticals (NASDAQ:SLXP) was upgraded from Neutral to Buy at UBS today. The stock closed yesterday at $96.99 on volume of 3.9 million shares, above average daily volume of 2.9 million. There is potential upside of 73.8% for shares of Salix Pharmaceuticals based on a current price of $96.99 and an average consensus analyst price target of $168.59. Salix Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $124.39 and find additional resistance at the 50-day MA of $142.49.
SLXP: 105.88 (+1.83)
